Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.32 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | PRKCA | P17252 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17637586 | 0.98 | DGKA (0.43) | DGKAEPHX2SMN1; SMN2ALOX12KMT2A | |
| SCHEMBL9972406 | 0.97 | DGKA (0.37) | DGKAEPHX2SMN1; SMN2ALOX12KMT2A | |
| SCHEMBL126873 | 0.93 | ADRA2A (0.33) | DGKAALOX12PSMB8PSMB5TDP1 | |
| SCHEMBL13041856 | 0.93 | ADRA2A (0.33) | DGKAALOX12PSMB8PSMB5TDP1 | |
| SCHEMBL10330543 | 0.93 | DGKA (0.39) | DGKAEPHX2SMN1; SMN2ALOX12KMT2A | |
| SCHEMBL7954092 | 0.92 | DGKA (0.40) | DGKASMN1; SMN2ALOX12KMT2AALDH1A1 | |
| SCHEMBL14437931 | 0.92 | DGKA (0.35) | DGKAEPHX2 | |
| SCHEMBL12285169 | 0.91 | EPHX2 (0.38) | DGKAEPHX2ALOX12KMT2APSMB8 | |
| SCHEMBL16368769 | 0.91 | DGKA (0.33) | DGKAEPHX2ALOX12PSMB8PSMB5 | |
| SCHEMBL13821165 | 0.91 | ALOX12 (0.35) | DGKAALOX12ALDH1A1L3MBTL1PSMB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11826485-B2 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| US-20170112939-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | Ascendis Pharma Ophthamology Division A/S (DK) | 2017-04-27 | — | — | US | disclosed |
| US-20160296600-A1 | Relaxin Prodrugs | ASCENDIS PHARMA RELAXIN DIVISION A/S (DK) | 2016-10-13 | — | — | US | disclosed |
| US-20160296600-A1 | Relaxin Prodrugs | ASCENDIS PHARMA RELAXIN DIVISION A/S (DK) | 2016-10-13 | — | — | US | disclosed |
| US-9457066-B2 | Prodrugs comprising an insulin linker conjugate | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2016-10-04 | — | — | US | disclosed |
| US-9457066-B2 | Prodrugs comprising an insulin linker conjugate | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2016-10-04 | — | — | US | disclosed |
| US-9393344-B2 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20160082123-A1 | Hydrogel-Linked Prodrugs Releasing Tagged Drugs | ASCENDIS PHARMA A/S (DK) | 2016-03-24 | — | — | US | disclosed |
| US-20120253071-A1 | Sterilization of biodegradable hydrogels | ASCENDIS PHARMA A/S (DK) | 2012-10-04 | — | — | US | disclosed |
| US-20120191039-A1 | CARRIER LINKED PRAMIPEXOLE PRODRUGS | ASCENDIS PHARMA A/S (DK) | 2012-07-26 | — | — | US | disclosed |
| US-20120191039-A1 | CARRIER LINKED PRAMIPEXOLE PRODRUGS | ASCENDIS PHARMA A/S (DK) | 2012-07-26 | — | — | US | disclosed |
| US-20120183616-A1 | LONG ACTING INSULIN COMPOSITION | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-07-19 | — | — | US | disclosed |
| US-20120184489-A1 | PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-07-19 | — | — | US | disclosed |
| US-20120184489-A1 | PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-07-19 | — | — | US | disclosed |
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2012-06-21 | — | — | US | disclosed |
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2012-06-21 | — | — | US | disclosed |
| US-20120156260-A1 | Prodrugs Containing an Aromatic Amine Connected By an Amido Bond to a Linker | ASCENDIS PHARMA A/S (DK) | 2012-06-21 | — | — | US | disclosed |
| US-20070196454-A1 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156260-A1 | Prodrugs Containing an Aromatic Amine Connected By an Amido Bond to a Linker | DAO, DNPEP, DDC | DGKA 2693/4885EPHX2 378/4885SMN1; SMN2 3107/4885 |
| US-20170112939-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | PDE6C, ALDH1A2, UACA | DGKA 2201/4885EPHX2 83/4885SMN1; SMN2 4722/4885 |
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | DGKA 1014/4885EPHX2 126/4885SMN1; SMN2 4736/4885 |
| US-20160296600-A1 | Relaxin Prodrugs | RXFP1, RXFP2, RXFP3 | DGKA 4264/4885EPHX2 1719/4885SMN1; SMN2 1072/4885 |
| US-20120184489-A1 | PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE | IAPP, IGF1R, INSR | DGKA 1749/4885EPHX2 2945/4885SMN1; SMN2 1009/4885 |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | DGKA 1014/4885EPHX2 126/4885SMN1; SMN2 4736/4885 |
| US-11826485-B2 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | PLOD3, LIG3, PLOD2 | DGKA 2661/4885EPHX2 168/4885SMN1; SMN2 2608/4885 |
| US-20070196454-A1 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | PLOD3, PLOD2, PLOD1 | DGKA 3230/4885EPHX2 301/4885SMN1; SMN2 2580/4885 |
| US-20120183616-A1 | LONG ACTING INSULIN COMPOSITION | IAPP, INSR, GPR119 | DGKA 1347/4885EPHX2 4394/4885SMN1; SMN2 626/4885 |
| US-20120253071-A1 | Sterilization of biodegradable hydrogels | USP3, USP30, USP4 | DGKA 1801/4885EPHX2 3321/4885SMN1; SMN2 4252/4885 |
| US-20120191039-A1 | CARRIER LINKED PRAMIPEXOLE PRODRUGS | PRAP1, LPXN, DNPEP | DGKA 3211/4885EPHX2 533/4885SMN1; SMN2 1191/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | DGKA 1014/4885EPHX2 126/4885SMN1; SMN2 4736/4885 |
| US-20160082123-A1 | Hydrogel-Linked Prodrugs Releasing Tagged Drugs | PTMS, PGLS, PAM | DGKA 2826/4885EPHX2 78/4885SMN1; SMN2 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.